Apyx Medical (APYX) Current Deferred Revenue (2019 - 2025)

Apyx Medical (APYX) has 7 years of Current Deferred Revenue data on file, last reported at $1.7 million in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue fell 15.0% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (down 15.0% YoY), and the FY2025 full-year result was $1.7 million, down 15.0% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $1.7 million, down from $2.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $2.3 million in Q4 2022 and bottomed at $1.7 million in Q4 2023.
• The 5-year median for Current Deferred Revenue is $1.9 million (2021), against an average of $1.9 million.
• The widest annual swing landed in 2021, when Current Deferred Revenue soared 216.67%; it then declined 26.09% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $1.9 million in 2021, then increased by 21.05% to $2.3 million in 2022, then declined by 26.09% to $1.7 million in 2023, then rose by 17.65% to $2.0 million in 2024, then retreated by 15.0% to $1.7 million in 2025.
• The last three Current Deferred Revenue figures came in at $1.7 million (Q4 2025), $2.0 million (Q4 2024), and $1.7 million (Q4 2023), per Business Quant data.

Peer Comparison